BlackRock’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $113K | Sell |
84,282
-114
| -0.1% | -$188 | ﹤0.01% | 4934 |
|
|
2025
Q4 | $135K | Buy |
84,396
+114
| +0.1% | +$235 | ﹤0.01% | 4823 |
|
|
2025
Q3 | $216K | Buy |
84,282
+66,504
| +374% | +$210K | ﹤0.01% | 4667 |
|
|
2025
Q2 | $32.2K | Sell |
17,778
-5,463
| -24% | -$9.04K | ﹤0.01% | 5069 |
|
|
2025
Q1 | $47.2K | Sell |
23,241
-547
| -2% | -$2.04K | ﹤0.01% | 4929 |
|
|
2024
Q4 | $142K | Buy |
23,788
+1,133
| +5% | +$9.47K | ﹤0.01% | 4693 |
|
|
2024
Q3 | $221K | Sell |
22,655
-4,888
| -18% | -$65.7K | ﹤0.01% | 4508 |
|
|
2024
Q2 | $564K | Sell |
27,543
-55,461
| -67% | -$1.86M | ﹤0.01% | 4317 |
|
|
2024
Q1 | $3.75M | Sell |
83,004
-2,884
| -3% | -$138K | ﹤0.01% | 3791 |
|
|
2023
Q4 | $4.05M | Buy |
85,888
+4,781
| +6% | +$266K | ﹤0.01% | 3770 |
|
|
2023
Q3 | $3.28M | Sell |
81,107
-5,720
| -7% | -$578K | ﹤0.01% | 3831 |
|
|
2023
Q2 | $9.25M | Buy |
86,827
+1,159
| +1% | +$386K | ﹤0.01% | 3455 |
|
|
2023
Q1 | $25.6M | Sell |
85,668
-5,765
| -6% | -$2.46M | ﹤0.01% | 2844 |
|
|
2022
Q4 | $31.4M | Sell |
91,433
-28
| -0% | -$6.77K | ﹤0.01% | 2778 |
|
|
2022
Q3 | $17.3M | Buy |
91,461
+2,502
| +3% | +$581K | ﹤0.01% | 3112 |
|
|
2022
Q2 | $18.8M | Buy |
88,959
+8,898
| +11% | +$1.87M | ﹤0.01% | 3122 |
|
|
2022
Q1 | $26.8M | Sell |
80,061
-542
| -0.7% | -$157K | ﹤0.01% | 2987 |
|
|
2021
Q4 | $26.2M | Buy |
80,603
+4,557
| +6% | +$1.96M | ﹤0.01% | 3117 |
|
|
2021
Q3 | $36.9M | Buy |
76,046
+5,271
| +7% | +$2.32M | ﹤0.01% | 2863 |
|
|
2021
Q2 | $32.9M | Buy |
70,775
+4,893
| +7% | +$2.67M | ﹤0.01% | 2987 |
|
|
2021
Q1 | $45.5M | Buy |
65,882
+9,644
| +17% | +$7.76M | ﹤0.01% | 2679 |
|
|
2020
Q4 | $41.6M | Buy |
56,238
+5,605
| +11% | +$4.37M | ﹤0.01% | 2585 |
|
|
2020
Q3 | $35.1M | Buy |
50,633
+5,578
| +12% | +$4.19M | ﹤0.01% | 2503 |
|
|
2020
Q2 | $38.2M | Buy |
45,055
+13,853
| +44% | +$9.03M | ﹤0.01% | 2406 |
|
|
2020
Q1 | $11.2M | Buy |
31,202
+6,167
| +25% | +$2.22M | ﹤0.01% | 2934 |
|
|
2019
Q4 | $5.85M | Buy |
25,035
+5,750
| +30% | +$578K | ﹤0.01% | 3457 |
|
|
2019
Q3 | $2.17M | Buy |
19,285
+588
| +3% | +$92.7K | ﹤0.01% | 3721 |
|
|
2019
Q2 | $3.28M | Buy |
18,697
+17,802
| +1,989% | +$3.02M | ﹤0.01% | 3638 |
|
|
2019
Q1 | $142K | Sell |
895
-62
| -6% | -$7.64K | ﹤0.01% | 4313 |
|
|
2018
Q4 | $59K | Sell |
957
-17
| -2% | -$1.43K | ﹤0.01% | 4453 |
|
|
2018
Q3 | $120K | Buy |
974
+39
| +4% | +$5.79K | ﹤0.01% | 4427 |
|
|
2018
Q2 | $137K | Buy |
+935
| New | +$143K | ﹤0.01% | 4397 |
|
Other funds holding BTAI
AC
OCM
VCM
VFT
BlackRock's BTAI Position: Q1 2026 in Review
BlackRock reduced its BioXcel Therapeutics (BTAI) stake by 0.14% in Q1 2026, selling an estimated $188 and leaving 84,282 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #4934.
BlackRock first reported a position in BTAI in Q2 2018 and has held it in 32 quarters since. The position peaked at $45.5M in Q1 2021. 40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.
- BlackRock held 84,282 shares of BioXcel Therapeutics worth $113K as of Q1 2026.
- BlackRock sold 114 BioXcel Therapeutics shares in Q1 2026, an estimated $188.
- BioXcel Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4934 holding.
- BlackRock first reported a position in BioXcel Therapeutics in Q2 2018 and has held it in 32 quarters since.
- BlackRock's BioXcel Therapeutics position peaked at $45.5M in Q1 2021.
- 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.